ORIC Pharmaceuticals presented its late-stage pipeline and updated financial position at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026.
The company reported $388 million in cash at the end of the second quarter, projecting a runway into the second half of 2028. ORIC holds a current ratio of 13.19 and a debt-to-equity ratio of just 0.02, according to CFO Dominic Piscitelli. The stock has climbed 52.81% year to date, and Wall Street analysts maintain a strong buy consensus with price targets ranging from $14 to $27 against a market capitalization of $1.31 billion.
The focal point of the presentation was rinzimetastat, ORIC's lead candidate targeting castration-resistant prostate cancer (CRPC) in patients who have progressed on abiraterone. The Phase III Himalayas-1 trial enrolled approximately 600 patients over roughly 16 months and will evaluate radiographic progression-free survival as its primary endpoint. Top-line data is expected in the first half of 2028. The control arm was powered for a PFS of 6.75 months. ORIC plans additional program updates in the second half of 2024, potentially covering enrollment progress, the second Phase III study, or earlier patient group data. Future expansion indications include Himalayas-2 (post-androgen-receptor-inhibitor CRPC) and Himalayas-3 (castration-sensitive prostate cancer).
Rinzimetastat targets the EED subunit of the PRC2 complex via allosteric inhibition, distinguishing it from Pfizer's mevrometostat, which targets the EZH2 enzymatic domain. ORIC highlighted a 20-hour clinical half-life for rinzimetastat versus a 4-to-5-hour half-life for mevrometostat. Rinzimetastat is dosed at 400 mg once daily combined with darolutamide, while mevrometostat requires gram-level doses alongside enzalutamide, a known CYP inducer. Pfizer has narrowed its MEVPRO-1 Phase III readout guidance to the fourth quarter of 2024.
On the oncology safety front, ORIC cited a 1.7% rate of secondary malignancies observed with Tazemetostat in clinical use, noting this fell well below the roughly 50% rate seen in preclinical rodent studies.
ORIC's second pipeline asset, enozertinib, targets EGFR exon 20 insertion mutations in non-small cell lung cancer. The company plans to present new data on atypical EGFR mutations as a poster at ESMO 2024. The target for initiating the first Phase III study is 2025. The total addressable market for EGFR exon 20 lung cancer in the U.S. is estimated at about $1.5 billion, or roughly 4,000 patients representing approximately 2% of non-small cell lung cancer. Atypical EGFR mutations account for about 6,000 patients, or 2.5% to 3%, with a U.S. market estimated at roughly $2.5 billion.
Regarding competitive benchmarks, ORIC noted that competitor systemic response rates in lung cancer sit in the low to mid-60% range, while CNS response rates have been as low as 30% or unreported. Approximately 35% to 40% of frontline lung cancer patients present with brain metastases.
In the post-abiraterone CRPC space, ORIC estimated the U.S. market at approximately $3.5 billion annually. For context, Bayer's darolutamide generated between $3 billion and $3.5 billion in annual revenue and is growing at more than 60% per year, the company noted.
